
               
               
               7 DRUG INTERACTIONS
               
               
                  
                     
                     
                     7.1 

Effect
of Other Drugs on Lenvatinib
                     
                        No dose adjustment of LENVIMA is recommended when co-administered with CYP3A, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) inhibitors and CYP3A and P-gp inducers [see Clinical Pharmacology (12.3)].
                     
                     
                  
               
            
         